

WHO GUIDELINE

on control and elimination of human schistosomiasis



WHO GUIDELINE

on control and elimination of human schistosomiasis

WHO guideline on control and elimination of human schistosomiasis

ISBN 978-92-4-004160-8 (electronic version)

ISBN 978-92-4-004161-5 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO guideline on control and elimination of human schistosomiasis. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	v
Abbreviations and acronyms	viii
Glossary	ix
Executive summary	xii
Summary of recommendations	xvi
1. Introduction	1
1.1 Assessment of conflicts of interest	3
1.2 Methods used to develop the guideline	3
1.2.1 Rating the certainty of evidence	3
1.2.2 Applying the evidence-to-decision framework	4
1.2.3 Systemic reviews supporting the guideline	4
1.2.4 Linkage of systematic reviews to recommendations	5
2. Background on human schistosomiasis	7
2.1 Epidemiology	7
2.2 Control and elimination strategies	8
Summary of evidence and rationale for recommendations	11
3. Implementing preventive chemotherapy based on prevalence of infection	12
3.1 Recommendations	12
3.2 Rationale	15
3.2.1 Impact of preventive chemotherapy on schistosomiasis morbidity in key population age groups	15
3.2.2 Optimal prevalence threshold for preventive chemotherapy to control morbidity	18
3.2.3 Frequency of praziquantel for preventive chemotherapy	23

4. Safety of praziquantel for treatment of schistosomiasis	27
4.1 Recommendation	27
4.2. Rationale	27
5. WASH and snail control interventions	31
5.1 Recommendation	31
5.2 Rationale	32
5.2.1 WASH interventions and schistosomiasis in at-risk populations	32
5.2.2 Chemical-based snail control in at-risk communities	35
6. Verification of interruption of transmission	38
6.1 Recommendation	38
6.2 Rationale	39
6.2.1 Diagnostic tools for detection of <i>Schistosoma</i> infection in humans to verify elimination of transmission	39
6.2.2 Diagnostic tools for detection of <i>Schistosoma</i> in snails and the environment to verify elimination of transmission	41
6.2.3 Diagnostic tools for detection of <i>Schistosoma</i> in non-human animal hosts to verify elimination of transmission	45
7. Dissemination, implementation and evaluation of the guideline	48
8. Future research needs	49
References	51
Annexes	61
Annex 1. List of contributors to the guideline	62
Annex 2. Summary of declarations of interests and their management	66
Annex 3. GRADE quality of evidence (certainty of evidence)	69
Annex 4. Evidence review, PICO questions and GRADE summary tables	70
Annex 5. Classes of intensity of schistosome infection	117
Annex 6. Estimated equivalent prevalence of point-of-care circulating cathodic antigen to single and duplicate slide Kato-Katz and suggested equivalent prevalence threshold for <i>Schistosoma mansoni</i>	118

Acknowledgements

The World Health Organization (WHO) is sincerely grateful to the many professionals from a range of backgrounds and specialities who contributed their time and expertise to the development of this guideline.

Guideline development group

The guideline development group was chaired by Paul Hagan (University of Hull, United Kingdom of Great Britain and Northern Ireland). The guideline methodologist and meeting co-chair was M. Hassan Murad (Mayo Clinic, Minnesota, United States of America).

Membership of the group comprised the following experts: Fernando Schemelzer M. Bezerra (Federal University of Ceara, Brazil), Daniel Colley (University of Georgia, United States of America), Fiona Fleming (Schistosomiasis Control Initiative Foundation, United Kingdom of Great Britain and Northern Ireland), Mamoun Homeida (Academy of Medical Sciences and Technology, Sudan), Narcis Kabatereine (Schistosomiasis Control Initiative Foundation, Uganda), Fatma Kabole (Ministry of Health Zanzibar, United Republic of Tanzania), Charles H. King (Case Western Reserve University, United States of America), Margaret A. Mafe (Nigerian Institute of Medical Research, Nigeria), Nicholas Midzi (University of Zimbabwe, Zimbabwe), Francisca Mutapi (University of Edinburgh, United Kingdom of Great Britain and Northern Ireland), Joseph Mwanga (National Institute for Medical Research, United Republic of Tanzania), Reda Ramzy (National Nutrition Institute, Egypt), Allen Ross (International Centre for Diarrhoeal Disease Research, Bangladesh), Fadjar Satrija (IPB University, Indonesia), J. Russell Stothard (Liverpool School of Tropical Medicine, United Kingdom of Great Britain and Northern Ireland), Mamadou Sounalo Traoré (National Institute for Research in Public Health, Mali), Jürg Utzinger (Swiss Tropical and Public Health Institute, Switzerland), Joanne P. Webster (Royal Veterinary College, United Kingdom of Great Britain and Northern Ireland) and Xiao-Nong Zhou (National Institute of Parasitic Diseases, China).

Guideline lead writer and editor

Nathan C. Lo (University of California, San Francisco, United States of America)

Systematic review team

The following researchers conducted the systematic reviews and developed the evidence profiles and GRADE tables: Anthony Danso-Appiah (University of Ghana, Ghana), Paolo Eusebi (Regional Health Authority of Umbria, Italy), Eric Sam Loker

(University of New Mexico, United States of America), Charles Owuora Obonyo (Kenya Medical Research Institute, Kenya), Reginald Quansah (University of Ghana, Ghana), Liang Song (University of Florida, United States of America) and Michel Vaillant (Luxembourg Institute of Health, Luxembourg).

External review group

The draft guideline was reviewed by the following experts who provided valuable input: Dhekra Amin Abdo Annuzaili (Independent consultant, Egypt), Moses Chimbari (University of KwaZulu-Natal, South Africa), Alan Fenwick (Schistosomiasis Control Initiative Foundation, United Kingdom of Great Britain and Northern Ireland), Hiroshi Ohmae (National Institute of Infectious Diseases, Japan), Winston A. Palasi (National Programme Coordinator Philippines), Otavio Pieri (Oswaldo Cruz Institute, Brazil), Lorenzo Savioli (Independent consultant, Switzerland) and Louis-Albert Tchuem Tchuente (Ministry of Health, Cameroon).

Guideline steering group

The members of the guideline steering group were: Bernadette Abela-Ridder (Veterinary Public Health, Vector Control and Environment, WHO Department of Control of Neglected Tropical Diseases), Gautam Biswas (Strategic Information and Analytics, WHO Department of Control of Neglected Tropical Diseases), Sophie Boisson (Water, Sanitation, Hygiene and Health, WHO Department of Environment, Climate Change and Health), Daniel Argaw Dagne (Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases), Albis Gabrielli (Strategic Information and Analytics, WHO Department of Control of Neglected Tropical Diseases), Amadou Garba-Djirmay (Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases), Jiagang Guo (Veterinary Public Health, Vector Control and Environment, WHO Department of Control of Neglected Tropical Diseases), Jonathan King (Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases), Ornella Lincetto (Newborn Health, WHO Department of Maternal, Newborn, Child & Adolescent Health & Ageing), Pamela Sabina Mbabazi (Strategic Information and Analytics, WHO Department of Control of Neglected Tropical Diseases), Mohamed Jamsheed (Vector-Borne and Neglected Tropical Diseases, WHO Regional Office for South-East Asia), Antonio Montresor (Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases), Pauline Mwinzi (Expanded Special Project for Elimination of Neglected Tropical Diseases, WHO Regional Office for

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23357

